Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenias in Cytotoxic T-lymphocyte Antigen-4 (CTLA4) Haploinsufficiency
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
At a glance
- Drugs Abatacept (Primary)
- Indications Leucopenia; Neutropenia; Pancytopenia; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 20 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Feb 2019 to 26 Feb 2019.
- 26 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Jan 2019 to 1 Feb 2019.
- 25 Jan 2019 Planned primary completion date changed from 31 Jul 2025 to 30 Jun 2019.